CCIA
AVDL

Campbell & Co Investment Adviser’s Avadel Pharmaceuticals AVDL Stock Holding History

Campbell & Co Investment Adviser’s Portfolio AVDL Stock Details AVDL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-38,458
Closed -$504K – 1058
2024
Q3 		$504K Buy
+38,458
New +$586K 0.04% 713

Other funds holding AVDL

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
GJL
Gendell Jeffrey L $7.34B AUM 183.72% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $5.05B AUM 164.99% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
WE
Wealth Effects Boston, Massachusetts $370M AUM 97.79% 1-Year Est. Return

Campbell & Co Investment Adviser's AVDL Position: Q4 2024 in Review

Campbell & Co Investment Adviser sold out of Avadel Pharmaceuticals (AVDL) in Q4 2024, closing a stake of 38,458 shares — an estimated $504K sold.

Campbell & Co Investment Adviser first reported a position in AVDL in Q3 2024 and held it in 1 quarter. The position peaked at $504K in Q3 2024. 159 funds tracked by Wall St. Rank hold AVDL as of Q4 2024.

  • Campbell & Co Investment Adviser reported no remaining Avadel Pharmaceuticals position as of Q4 2024 after selling out during the quarter.
  • Campbell & Co Investment Adviser sold 38,458 Avadel Pharmaceuticals shares in Q4 2024, an estimated $504K.
  • Campbell & Co Investment Adviser first reported a position in Avadel Pharmaceuticals in Q3 2024 and held it in 1 quarter.
  • Campbell & Co Investment Adviser's Avadel Pharmaceuticals position peaked at $504K in Q3 2024.
  • 159 funds tracked by Wall St. Rank held Avadel Pharmaceuticals as of Q4 2024.

Based on Campbell & Co Investment Adviser's 13F filing for Q4 2024, filed 10 Feb 2025.